Bicycle Therapeutics (BCYC) Expected to Announce Quarterly Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $7.0760 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 2:00 AM ET.

Bicycle Therapeutics Stock Performance

BCYC opened at $5.37 on Friday. Bicycle Therapeutics has a 1 year low of $5.03 and a 1 year high of $12.60. The firm has a 50 day moving average price of $6.44 and a 200 day moving average price of $7.04. The company has a market cap of $372.52 million, a PE ratio of -1.48 and a beta of 1.63.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Jefferies Financial Group raised shares of Bicycle Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 17th. Citigroup reiterated an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Royal Bank Of Canada restated a “sector perform” rating and set a $11.00 price objective (down previously from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Truist Financial began coverage on Bicycle Therapeutics in a research report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.11.

Insider Activity

In other Bicycle Therapeutics news, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the completion of the sale, the chief financial officer owned 87,081 shares in the company, valued at $565,155.69. This trade represents a 4.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the sale, the chief executive officer owned 618,996 shares in the company, valued at $3,998,714.16. This represents a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,029 shares of company stock valued at $251,966 over the last 90 days. Insiders own 22.90% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Brooklyn Investment Group bought a new stake in shares of Bicycle Therapeutics in the fourth quarter worth $69,000. Ausdal Financial Partners Inc. acquired a new position in Bicycle Therapeutics during the 2nd quarter worth $70,000. Invesco Ltd. bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth about $71,000. Vontobel Holding Ltd. bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth about $71,000. Finally, Sei Investments Co. acquired a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at about $74,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.